- Previous Close
2.4300 - Open
2.4000 - Bid 2.7100 x 100
- Ask 2.7900 x 100
- Day's Range
2.4000 - 2.8000 - 52 Week Range
2.1900 - 4.2000 - Volume
86,321 - Avg. Volume
42,081 - Market Cap (intraday)
22.498M - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5100 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.33
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
www.lisata.comRecent News: LSTA
View MorePerformance Overview: LSTA
Trailing total returns as of 1/24/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LSTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LSTA
View MoreValuation Measures
Market Cap
22.50M
Enterprise Value
-13.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.67
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.72%
Return on Equity (ttm)
-44.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.07M
Diluted EPS (ttm)
-2.5100
Balance Sheet and Cash Flow
Total Cash (mrq)
38.26M
Total Debt/Equity (mrq)
0.59%
Levered Free Cash Flow (ttm)
-13.25M